Skip to main content

Advertisement

Log in

Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a multisystem disease, the pathogenesis of which remains undetermined. Following two microarray studies, we reported the differential expression of 88 human genes in patients with CFS; 85 of these genes were upregulated and 3 were downregulated. The top functional categories of these 88 genes were hematologic disease and function, immunologic disease and function, cancer, cell death, immune response, and infection. Clustering of quantitative polymerase chain reaction data from CFS/ME patients revealed seven subtypes with distinct differences in Short Form (SF)-36 scores, clinical phenotypes, and severity. Gene signatures in each subtype implicate five human genes as possible targets for specific therapy. Development of a diagnostic test for subtype status is now a priority. The possibility that these subtypes represent individual host responses to particular microbial infections is being investigated and may provide another route to specific therapies for CFS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fukuda K, Straus SE, Hickie I, et al.: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121:953–959.

    PubMed  CAS  Google Scholar 

  2. Department of Health: A Report of the CFS/ME Working Group. Available at http://www.doh.gov.uk/cmo/cfsmereport/. Accessed on January 22, 2002.

  3. Papanicolaou DA, Amsterdam JD, Levine S, et al.: Neuroendocrine aspects of chronic fatigue syndrome. Neuroimmunomodulation 2004, 11:65–74.

    Article  PubMed  CAS  Google Scholar 

  4. Komaroff AL, Buchwald D: Chronic fatigue syndrome: an update. Annu Rev Med 1998, 49:1–13.

    Article  PubMed  CAS  Google Scholar 

  5. Devanur LD, Kerr JR: Chronic fatigue syndrome. J Clin Virol 2006, 37:139–150.

    Article  PubMed  CAS  Google Scholar 

  6. Vernon SD, Unger ER, Dimulescu IM, et al.: Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers 2002, 18:193–199.

    PubMed  CAS  Google Scholar 

  7. Powell R, Ren J, Lewith G, et al.: Identification of novel expressed sequences, up-regulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy 2003, 33:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  8. Whistler T, Unger ER, Nisenbaum R, Vernon SD: Integration of gene expression, clinical, and epidemiologic data to characterize chronic fatigue syndrome. J Transl Med 2003, 1:10–18.

    Article  PubMed  Google Scholar 

  9. Whistler T, Jones JF, Unger ER, Vernon SD: Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol 2005, 5:5.

    Article  PubMed  Google Scholar 

  10. Whistler T, Taylor R, Craddock RC, et al.: Gene expression correlates of unexplained fatigue. Pharmacogenomics 2006, 7:395–405.

    Article  PubMed  CAS  Google Scholar 

  11. Grans H, Nilsson M, Dahlman-Wright K, Evengard B: Reduced levels of oestrogen receptor beta mRNA in Swedish patients with chronic fatigue syndrome. J Clin Pathol 2007, 60:195–198.

    Article  PubMed  CAS  Google Scholar 

  12. Grans H, Nilsson P, Evengard B: Gene expression profiling in the chronic fatigue syndrome. J Intern Med 2005, 258:388–390.

    Article  PubMed  CAS  Google Scholar 

  13. Kaushik N, Fear D, Richards SC, et al.: Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005, 58:826–832.

    Article  PubMed  CAS  Google Scholar 

  14. Carmel L, Efroni S, White PD, et al.: Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006, 7:375–386.

    Article  PubMed  CAS  Google Scholar 

  15. Broderick G, Craddock RC, Whistler T, et al.: Identifying illness parameters in fatiguing syndromes using classical project:tion methods. Pharmacogenomics 2006, 7:407–419.

    Article  PubMed  CAS  Google Scholar 

  16. Fang H, Xie Q, Boneva R, et al.: Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics 2006, 7:429–440.

    Article  PubMed  CAS  Google Scholar 

  17. Fostel J, Boneva R, Lloyd A: Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. Pharmacogenomics 2006, 7:441–454.

    Article  PubMed  CAS  Google Scholar 

  18. Kerr JR, Petty R, Burke B, et al.: Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis 2008, 197:1171–1184.

    Article  PubMed  CAS  Google Scholar 

  19. Zheng Z, Wu J, Sun Z: An approach to identify over-represented cis-elements in related sequences. Nucleic Acids Res 2003, 31:1995–2005.

    Article  PubMed  CAS  Google Scholar 

  20. Kerr JR, Burke B, Petty R, et al.: Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol 2008, 61:730–739.

    Article  PubMed  CAS  Google Scholar 

  21. Jason LA, Corradi K, Torres-Harding S, et al.: Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev 2005, 15:29–58.

    Article  PubMed  Google Scholar 

  22. Janal MN, Ciccone DS, Natelson BH: Sub-typing CFS patients on the basis of ‘minor’ symptoms. Biol Psychol 2006, 73:124–131.

    Article  PubMed  Google Scholar 

  23. Kerr JR, Christian P, Hodgetts A, et al.: Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments. J Clin Pathol 2007, 60:113–116.

    Article  PubMed  CAS  Google Scholar 

  24. Sairenji T, Yamanishi K, Tachibana Y, et al.: Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 1995, 38:269–273.

    Article  PubMed  CAS  Google Scholar 

  25. White PD, Thomas JM, Kangro HO, et al.: Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 2001, 358:1946–1954.

    Article  PubMed  CAS  Google Scholar 

  26. Kerr JR, Bracewell J, Laing I, et al.: Chronic fatigue syndrome (CFS) and arthralgia following parvovirus B19 infection. J Rheumatol 2002, 29:595–602.

    PubMed  Google Scholar 

  27. Chia JK, Chia A: Diverse etiologies for chronic fatigue syndrome. Clin Infect Dis 2003, 36:671–672

    Article  PubMed  Google Scholar 

  28. Chia JK: The role of enterovirus in chronic fatigue syndrome. J Clin Pathol 2005, 58:1126–1132.

    Article  PubMed  CAS  Google Scholar 

  29. Chia JK, Chia AY: Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol 2008, 61:43–48.

    Article  PubMed  CAS  Google Scholar 

  30. Chia JK, Chia LY: Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis 1999, 29:452–453.

    Article  PubMed  CAS  Google Scholar 

  31. Ayres JG, Flint N, Smith EG, et al.: Post-infection fatigue syndrome following Q fever. Q J Med 1998, 91:105–123.

    CAS  Google Scholar 

  32. Lamprecht K: Pilot study of etanercept treatment in patients with chronic fatigue syndrome. Meeting of the American Association of Chronic Fatigue Syndrome (AACFS). Seattle, WA; 2001. Available at http://cfs-news.org/accfs-ol.htm. Accessed on September 1, 2008.

  33. Kerr JR, Cunniffe VS, Kelleher P, et al.: Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis 2003, 36:e100–e106.

    Article  PubMed  CAS  Google Scholar 

  34. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT: Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007, 21:707–713.

    PubMed  CAS  Google Scholar 

  35. Kogelnik AM, Loomis K, Hoegh-Petersen M, et al.: Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006, 37(Suppl 1):S33–S38.

    Article  PubMed  CAS  Google Scholar 

  36. Arashima Y, Kato K, Komiya T, et al.: Improvement of chronic nonspecific symptoms by long-term minocycline treatment in Japanese patients with Coxiella burnetii infection considered to have post-Q fever fatigue syndrome. Intern Med 2004, 43:49–54.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jonathan R. Kerr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerr, J.R. Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Curr Rheumatol Rep 10, 482–491 (2008). https://doi.org/10.1007/s11926-008-0079-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0079-5

Keywords

Navigation